BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8398693)

  • 1. The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.
    Skarsgard LD; Skwarchuk MW; Vinczan A; Chaplin DJ
    Br J Cancer; 1993 Oct; 68(4):681-3. PubMed ID: 8398693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.
    Skarsgard LD; Vinczan A; Skwarchuk MW; Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):363-7. PubMed ID: 8195034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
    Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
    Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
    Keohane A; Godden J; Stratford IJ; Adams GE
    Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH; Siim BG; Evans JW; Brown JM
    Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
    Minchinton AI; Brown JM
    Br J Cancer; 1992 Dec; 66(6):1053-8. PubMed ID: 1457345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH.
    Tocher JH; Virk NS; Edwards DI
    Biochem Pharmacol; 1990 Sep; 40(6):1405-10. PubMed ID: 2144963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
    Chinje EC; Cowen RL; Feng J; Sharma SP; Wind NS; Harris AL; Stratford IJ
    Mol Pharmacol; 2003 Jun; 63(6):1248-55. PubMed ID: 12761334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM
    Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
    Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
    Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
    Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG; van Zijl PL; Brown JM
    Br J Cancer; 1996 Apr; 73(8):952-60. PubMed ID: 8611431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
    Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
    Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
    Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
    J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
    Brown JM
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
    Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
    J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M; Stevens G
    Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay.
    Stratford IJ; Stephens MA
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):973-6. PubMed ID: 2495261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice.
    Durand RE; Olive PL
    Radiat Oncol Investig; 1997; 5(5):213-9. PubMed ID: 9372543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, structure and hypoxic cytotoxicity of 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
    Jiang F; Weng Q; Sheng R; Xia Q; He Q; Yang B; Hu Y
    Arch Pharm (Weinheim); 2007 May; 340(5):258-63. PubMed ID: 17464965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.